Chemical technologies underpin almost every aspect of our lives, from the energy we use to the materials we rely on and the medications we take. The UK chemical industry generates £73.3 billion revenue and employs 161,000 highly skilled workers. It is highly diverse (therefore resilient) with SMEs and microbusinesses making up a remarkable 96% of the sector. Today's global chemicals industry is responsible for 10% of greenhouse gas (GHG) emissions and consumes 20% of oil and gas as carbon feedstock to make products. Decarbonisation (defossilisation) of the chemicals sector is, therefore, urgently required, but to do so presents major technical and societal challenges. New sustainable chemical technologies, enabled by new synthesis, catalysis, reaction engineering, digitalisation and sustainability assessment, are needed. In order to ensure that the UK develops a resource efficient, resilient and sustainable economy underpinned by chemical manufacturing, developments in chemical technologies must be closely informed by whole systems approaches to measure and minimise environmental footprints, understand supply chains and assess economic and technological viability, using techniques such as life cycle assessment and material flow analysis. Lack of access to experts in science and engineering with a holistic understanding of sustainable systems is widely and publicly recognised as a significant risk. It is therefore extremely timely to establish a new EPSRC CDT in Sustainable Chemical Technologies that fully integrates a whole systems approach to training and world leading research in an innovation-driven context. This CDT will train the next generation of leaders in sustainable chemical technologies with new skills to address the growing demand for highly skilled PhD graduates with the ability to develop and transfer sustainable practices into industry and society. The new CDT will be a unique and vibrant focus of innovative doctoral training in the UK by taking full advantage of two exciting new developments at Bath. First, the CDT will be embedded in our new Institute for Sustainability (IfS) which has evolved from the internationally leading Centre for Sustainable and Circular Technologies (CSCT) and which fully integrates whole systems research and sustainable chemical technologies - two world-leading research groupings at Bath - under one banner. Second, the CDT will operate in close partnership with our recently established Swindon-based Innovation Centre for Applied Sustainable Technologies (iCAST, www.iCAST.org.uk) a £17M partnership for the rapid translation of university research to provide a dynamic innovation-focused context for PhD training in the region. Our fresh and dynamic approach has been co-created with key industrial, research, training and civic partners who have indicated co-investment of over £17M of support. This unique partnership will ensure that a new generation of highly skilled, entrepreneurial, innovative PhD graduates is nurtured to be the leaders of tomorrow's green industrial revolution in the UK.

Research at the intersection of biology and engineering has expanded our understanding of living systems and the many unique and valuable capabilities they possess. Scientists and engineers have now begun to harness this knowledge in new ways to address some of humanity's most pressing challenges. For example, using engineered biosystems we can create innovative healthcare solutions, enable more sustainable forms of agriculture, and support clean manufacturing methods. The emerging field of Engineering Biology aims to harness biology to build technologies for a healthy, sustainable, and equitable future. However, to date the lack of a rigorous biological engineering process has resulted in biosystems that are fragile, unpredictable, and difficult to scale when applied in real-world settings. Early pioneers in fields ranging from Aerospace to Information Technologies faced similar challenges when attempting to create robust and reliable systems. Such difficulties were oftentimes overcome using methods from systems and control engineering, which enabled rigorous approaches to the design, optimisation, and realisation of engineered systems, ultimately leading to dramatic economic growth and the creation of entirely new industries. To achieve an equivalent step-change in the engineering of reliable and robust biological systems, our programme will develop similar control and Artificial Intelligence systems in biotechnology - which we term feedback biocontrollers. These biocontrollers will be designed to operate within cells, between cells, and even to interact with non-biological entities (such as computers), thereby allowing researchers and innovators to efficiently and safely harness engineered biology in its many real-world applications. The robust engineering of biological control systems will be underpinned by the development of four "Engineering Pillars". These cover Theory (mathematical/AI approaches based on systems and control theory to model, design, analyse, and optimise biosystems), Software (computational tools able to translate this theory into conceptual designs), Wetware (experimental methods and biological parts to make designs a biological reality), and Hardware (to comprehensively test, scale-up, and deploy engineered biosystems). Each Pillar feeds directly into an integrated "Design-Build-Test-Learn" cycle rooted in systems and control engineering methods, which will accelerate academic and industrial development of new biotechnologies. Technologies developed in each Engineering Pillar will be integrated to address outstanding problems in three "Grand Challenge'' application domains: Biomedicine, Agriculture, and the Environment. Our team will work with industrial partners to generate world-leading solutions for each of these areas, demonstrating how biocontrollers can revolutionise scale-up and deployment of reliable engineered biotechnologies. The EEBio programme represents a timely investment in the new field of Engineering Biology which is set to play a defining role in the future of our society and the rapidly growing Bioeconomy. Our team of world-leading experts and up-and-coming early career researchers will create tools and technologies that are key to the effective engineering of biological systems - as observed in other, mature engineering fields - but which are not yet realised for Engineering Biology. EEBio brings together recent momentum across our team for rapid impact, while also supporting development of seminal ideas; in the near-term this will help address Grand Challenges we face today, while in the long-term it will provide the foundation for many bio-based solutions that will improve human life, agriculture, and the environment. Our work will accelerate responsible industrial exploitation, open up the field to other research communities (in the life, medical and social sciences), and support public confidence in the safety and reliability of Engineering Biology.

We will train a cohort of students at the interface between the physical and computer sciences to drive the critically needed implementation of digital and automated methods in chemistry and materials. Through such training, each student will develop a common language across the areas of automation, AI, synthesis, characterization and modelling, preparing them to become both leader and team player in this evolving and multifaceted research landscape. The lack of skilled individuals is one of the main obstacles to unlocking the potential of digital materials research. This is demonstrated by the enthusiastic response toward this proposal from our industrial partners, who span sectors and sizes: already 35 are involved and we have already received cash support corresponding to over 27 full studentships. This proposal will deliver the EPRSC strategic priority "Physical and Mathematical Sciences Powerhouse" by training in "discovery research in areas of potential high reward, connecting with industry and other partners to accelerate translation in areas such as catalysis, digital chemistry and materials discovery." The CDT training programme is based on a unique physical and intellectual infrastructure at the University of Liverpool. The Materials Innovation Factory (MIF) was established to deliver the vision of digital materials research in partnership with industry: it now co-locates over 100 industrial scientists from more than 15 companies with over 200 academic researchers. Since 2017, academics and industrial researchers from physical sciences, engineering and computer sciences have co-developed the intellectual environment, infrastructure and expertise to train scientists across these areas. To date, more than 40 PhD projects have been co-designed with and sponsored by our core industrial partners in the areas of organic, inorganic, hybrid, composite and formulated materials. Through this process, we have developed bespoke training in data science, AI, robotics, leadership, and computational methods. Now, this activity must be grown scalably and sustainably to match the rapidly increasing demand from our core partners and beyond. This CDT proposal, developed from our previous experience, allows us to significantly extend into new sectors and to a much larger number of partners, including late adopters of digital technologies. In particular, we can now reach SMEs, which currently have limited options to explore digitalization pathways without substantial initial investment. A distinctive and exciting training environment will be built exploiting the diverse background of the students. Peer learning and group activities within a cross-disciplinary team will accelerate the development of a common language. The ability to use a combination of skills from different individuals with distinct domain expertise to solve complex problems will build the teams capable of driving the necessary change in industry and academia. The professional training will reflect the diversity of career opportunities available to this cohort in industry, academia and non-commercial research organizations. Each component will be bespoke for scientists in the domain of materials research (Entrepreneurship, Chemical Supply Chain, Science Policy, Regulatory Framework). External partners of training will bring different and novel perspectives (corporate, SMEs, start-ups, international academics but also charities, local authorities, consultancy firms). Cohort activities span the entire duration of the training, without formal division between "training" and "research" periods, exploiting the physical infrastructure of MIF and its open access area to foster a strong and vital sense of community. We will embed EDI principles in all aspects of the CDT (e.g. recruitment, student well-being, composition of management, supervisory and advisory teams) to make it a pervasive component of the student experience and professional training.

Synthetic Biology is a growing field of science that combines Biosciences, Chemistry, Physics, Information Technology and Engineering, and involves the redesigning end engineering of organisms for functional purposes, for example to produce valuable substances (e.g. medicines) or gain new functions (e.g. sensing and responding to something in the environment). Synthetic Biology aspires to tackle grand challenges surpassing what is possible through traditional technologies: it has wide-ranging applications in healthcare, environmental protection, energy, agriculture, computing, advanced chemicals and materials. Synthetic Biology has grown significantly in the UK over the past decade, thanks to a >£400M investment via the Synthetic Biology for Growth Programme. One of the key investments has been the SynBioCDT: the first UK CDT in Synthetic Biology funded in 2014 by the EPSRC and BBSRC and run by the Universities of Oxford, Bristol and Warwick. The SynBioCDT trained 79 excellent PhD students selected from >650 applicants, and attracted support from industrial, academic and public-facing partners. Our graduate students have gone on to work within the bioeconomy and have established disruptive start-ups. The term "Engineering Biology" has been recently adopted to highlight the essential transition of Synthetic Biology into a mature Engineering discipline. The recent UKRI National Engineering Biology Programme (NEBP) sets the UK ambition for the field and encompasses the capabilities that can support the exploitation of Engineering Biology for economic and public benefit. The Universities of Bristol and Oxford aim to establish a new CDT in Engineering Biology, the EngBioCDT, to train the academic and industrial Engineering Biology leaders of tomorrow, and to equip them with skills needed to contribute toward scalable, robust, and transformative engineering of biomimetic and biological systems. The EngBioCDT builds on our experience with the SynBioCDT and will address the NEBP requirement for a new generation of biological engineers able to translate cutting-edge science into real-world impact; it will support the EPSRC focus area 'Frontiers in Engineering and Technology'. The EngBioCDT will enable cohesive cohorts of students to gain expertise in the design, modelling and engineering of biological components and systems; to understand broad concepts ranging from biomolecular interactions to cell function; and to augment the Engineering Biology approach with robotics, automation and AI. Students will obtain advanced skills in programming and engineering; implement biological design across scales; place research in the context of both basic and applied science; and become cognisant of challenges such as process development and scale-up in biotechnology. Students will undertake both group and individual projects before starting their doctoral project. The EngBioCDT will take advantage of the expertise provided by the two Universities and our industrial partners, which will all be catalysts for inter-University and inter-sector training and research. Students will also have superb opportunities to engage with leading international academics, for example through an annual Summer School, and by participating in international conferences and workshops. The environment is exceptional. Bristol hosted BrisSynBio, one of six UKRI-funded Synthetic Biology Research Centres, and now hosts the Bristol BioDesign Institute and the Bristol Centre for Engineering Biology; the CDT Director is a EPSRC Fellow. Oxford, which led the SynBioCDT, received three fellowships and a programme grant in Engineering Biology, and offers vibrant translational opportunities. The applicants provide expertise in graduate training and many of them have previously worked together effectively. Our pool of >70 supervisors reflects the truly multidisciplinary nature of Engineering Biology, and includes internationally renowned researchers.

The Covid-19 pandemic continues to take a huge toll - an estimated 6.3m people have died including 178,000 in the UK. Globally 1.6bn students have missed school, 250m people will be pushed into extreme poverty and economic losses are estimated at £12tr. History shows that epidemic and pandemic threats constantly emerge, whilst SARS-CoV-2 continues to mutate as it becomes endemic. It is clear that major losses could be prevented by sustained domestic investment in public health. Work undertaken within Vax-Hub1 on responsive technologies and accelerated quality control methods enabled rapid development and manufacture of the ChAdOx1 vectored vaccine against SARS-CoV-2 (licensed for emergency use in December 2020 via a non-profit partnership with AstraZeneca). Over 2.9bn doses have now been released in 180 countries. The UK had a leading role during the pandemic and the proposed Hub builds on this success to advance novel research on a broader range of technologies. Working closely with stakeholders, Vax-Hub will enable the UK to be better prepared for the next pandemic. This investment into The Future Vaccine Manufacturing Hub will enable our vision to make the UK the global centre for vaccine discovery, development and manufacture. The Vaccine Manufacturing Hub brings together a world-class multidisciplinary team with decades of cumulative experience in all aspects of vaccine design and manufacturing research. This Hub will bring academia, industry, not-for-profit organizations and policy makers together to propose radical change in vaccine development and manufacturing technologies, building on a technological innovation culture. The Hub will enhance future vaccine manufacturing through (i) de-risked manufacture of new vaccines by strategically innovating for a selected range of the most promising platform technologies (established and novel/disruptive); (ii) developing manufacturing options that improve the product quality and so immunogenicity; (iii) streamlined manufacturing process development with novel responsive solutions and advanced digitalisation strategies; (iii) a focus on enhancing stability and needle-free administration routes so they become a reality within the lifetime of the Hub. The proposed Hub would be the natural location for early-stage research before projects are transferred to a GMP manufacturing facility. The work focuses on development of improved vaccine platforms which can be flexible enough to be used for multiple product manufacture. These improved vaccine technologies are used as case studies to test rapid and responsive development tools to create a whole process mimicking vaccine manufacture, which could be easily and quickly deployed in case of epidemic/pandemic scenario. Finally the research focuses on standard and novel adjuvants to make mucosal delivery a reality, thus allowing alternative route to injection for mass administration. The Hub will establish the UK as the global centre for end-to-end vaccine research and manufacture. Additionally, vaccines should be considered a national security priority, as it is evident that diseases do not respect international boundaries, thus this work into capacity building and rapid response is a significant advantage. The impact of this Hub will be felt internationally, as the UK reaffirms its leadership in Global Health and works to ensure that the outputs of this Hub reach the global community and the most vulnerable, especially children.